Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IWWM-11 2022 | Predicting patient response to BTK inhibitors using novel approaches

Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, briefly discusses the importance of using novel approaches to predict patient response to Bruton’s tyrosine kinase (BTK) inhibitor therapy. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.